Inclusion Criteria:  PsA patients in CorEvitas initiating tofacitinib monotherapy or in combination with oral small molecules (eg methotrexate, leflunomide, sulfasalazine, apremilast) after 14 December 2017 (market approval of tofacitinib in the US) with no prior use of tofacitinib. Only the patient's first initiation after December 14, 2017 will be included in the analysis Have a 6 month follow-up visit (with ±3 month window)  Exclusion Criteria:  Patients taking tofacitinib in combination with any other bDMARD